U.S. Markets closed

Here's Why Urovant Sciences Got Whacked on "Positive" Clinical Trial Data

Brian Orelli, The Motley Fool

What happened

Urovant Sciences (NASDAQ:UROV) claimed victory in its press release today with the headline noting "positive" top-line data for its phase 3 study testing vibegron in patients with overactive bladder.

But investors rightfully looked past the top-line results, sending shares down 21% as of 2:07 p.m. EDT on Tuesday.

Paper with diagnosis overactive bladder written on it, next to paper labeled hematology results, stethoscope, and other medical items.

Image source: Getty Images.

So what

The good news is that vibegron works much better than nothing at all. The drug improved daily urge urinary incontinence (involuntary urine leakage) episodes and daily micturitions (a medically polite way of saying going pee) compared to a placebo by a statistically significant margin. And the drug significantly beat the placebo in all seven secondary endpoints.

That data should be enough to get the drug past the Food and Drug Administration and on the market.

But the clinical trial also included a group of patients who were given tolterodine ER, a chep generic drug for overactive bladder. Comparing the two drugs, vibegron looks a little better than tolterodine ER, but not by much.

Vibegron reduced daily urge urinary incontinence episodes by 2 episodes per day, compared with a reduction of 1.8 episodes for tolterodine ER. Similarly, micturitions were reduced by 1.8 per day for vibegron, compared to a reduction of 1.6 micturitions for tolterodine ER.

So it comes down to one question: What's 0.2 fewer daily trips to the bathroom worth to a patient? Most co-pays for branded drugs are double or more the co-pays for generics.

Urovant also hopes to peg vibegron as a safer alternative to tolterodine ER, which might justify the higher cost. There's some evidence supporting vibegron's safety in the top-line data: Of the patients taking vibegron, 1.7% reported high blood pressure, the same rate that was observed in the placebo group, and lower than the 2.6% incidence in the tolterodine ER group. But investors will have to wait until the full details of the study are reported at the American Urological Association Annual Meeting in May to see a full comparison of safety.

Now what

Urovant has gotten past the first hurdle, but it has a long road ahead.

In addition to competing with tolterodine ER, vibegron will also have to compete against Astellas ' Myrbetriq. Going up against the large Japanese pharma won't be easy for tiny Urovant, and it's hard to see a potential partner getting too excited about the data presented today.

More From The Motley Fool

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .